JPMorgan downgraded NanoString NSTG) to Neutral from Overweight without a price target. On November 17, the U.S. District Court for the District of Delaware determined that NanoString’s GeoMx infringed on seven patents owned by Prognosys and exclusively licensed by 10x Genomics (TXG), the analyst tells investors in a research note. The firm remains bullish on the spatial market overall and acknowledges that NanoString’s spatial portfolio is competitive and has been getting traction across the scientific community. However, Morgan Stanley sees limited visibility given the pending litigation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NSTG:
- Biotech Alert: Searches spiking for these stocks today
- NanoString files to sell 16M shares of common stock for holders
- NanoString downgraded to Neutral from Outperform at Baird
- NanoString downgraded to Market Perform at TD Cowen after 10x Genomics ruling
- NanoString downgraded to Market Perform from Outperform at TD Cowen